MedPath

Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma

Phase 2
Completed
Conditions
Colorectal Carcinoma
Registration Number
NCT00051987
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Brief Summary

The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and your cancer.

Detailed Description

In this study, patients with colorectal cancer that is no longer responding to standard medical treatment with irinotecan or an irinotecan containing treatment will be randomized to treatment with VELCADE alone or to treatment with VELCADE in combination with irinotecan.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
175
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (22)

USC/Norris Comprehensive Cancer Center

🇺🇸

Los Angeles, California, United States

California Cancer Center

🇺🇸

Greenbrae, California, United States

St. Lukes Rossevelt Hospital

🇺🇸

New York, New York, United States

West Michigan Regional Cancer and Blood Center

🇺🇸

Ludington, Michigan, United States

Oregon Health Sciences

🇺🇸

Portland, Oregon, United States

Alta Bates Comprehensive Cancer Center

🇺🇸

Berkley, California, United States

H. Lee Moffit Cancer Center

🇺🇸

Tampa, Florida, United States

New York University

🇺🇸

New York, New York, United States

Memphis Cancer Center, PC

🇺🇸

Memphis, Tennessee, United States

UNC School of Medicine

🇺🇸

Chapel Hill, North Carolina, United States

University of Texas Health Sciences Center at San Antonio

🇺🇸

San Antonio, Texas, United States

Cooper Green Hospital / Jefferson Clinic P.C.

🇺🇸

Birmingham, Alabama, United States

City of Hope Medical Group

🇺🇸

Pasadena, California, United States

Kentuckiana Cancer Institute, PLLC

🇺🇸

Louisville, Kentucky, United States

Bond Clinic Inc.

🇺🇸

Rolla, Missouri, United States

Rush Cancer Institute

🇺🇸

Chicago, Illinois, United States

Ohio State University Medical Center

🇺🇸

Columbus, Ohio, United States

Norris Cotton Cancer Center

🇺🇸

Lebanon, New Hampshire, United States

The Cancer Institute of New Jersey

🇺🇸

New Brunswick, New Jersey, United States

Arkansas Cancer Center

🇺🇸

Pine Bluff, Arkansas, United States

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Nevada Cancer Center

🇺🇸

Las Vegas, Nevada, United States

© Copyright 2025. All Rights Reserved by MedPath